GlassScriptPhysician profile
Kallie E Allender
NPI 1043631484
$2,080.35
in general payments reported to CMS, 2019-2025
16 companies · $16.25 in 2025
The $16.25 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,241 · 2022: $505 · 2023: $179 · 2024: $139 · 2025: $16.25.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $334.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $334.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,004.94 | 2021-2025 | |
| Lilly USA, LLC | $456.30 | 2021-2024 | Mounjaro, Zepbound |
| Novo Nordisk INC | $151.70 | 2021-2023 | Wegovy |
| Biohaven Pharmaceuticals, INC. | $76.11 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $71.07 | 2021-2024 | Farxiga, Breztri |
| Amgen INC. | $59.21 | 2021-2022 | |
| Axsome Therapeutics, INC. | $43.74 | 2023-2024 | Auvelity |
| Lundbeck LLC | $43.27 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $39.01 | 2021 | |
| Supernus Pharmaceuticals, INC. | $32.71 | 2021 | |
| Galderma Laboratories, L.P. | $23.17 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.10 | 2021 | |
| Avanir Pharmaceuticals, INC. | $16.60 | 2022 | |
| Upsher-Smith Laboratories LLC | $15.11 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.69 | 2024 | Xifaxan |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $13.62 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kallie Allender listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.